T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
CD6 is associated with T-cell modulation and is implicated in several autoimmune diseases. We previously demonstrated that Itolizumab, a CD6 domain 1 (CD6D1) specific humanized monoclonal antibody, inhibited the proliferation and cytokine production by T lymphocytes stimulated with anti-CD3 antibody...
Main Authors: | Usha Bughani, Arindam Saha, Anshu Kuriakose, Reshmi Nair, Ravindra B Sadashivarao, Rasika Venkataraman, Swati Patel, Anuja Tushar Deshchougule, Satish Kumar S, Enrique Montero, Harish V Pai, Dinesh V Palanivelu, Ramakrishnan Melarkode, Pradip Nair |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5495335?pdf=render |
Similar Items
-
Itolizumab in psoriasis
by: Ankita Srivastava
Published: (2017-01-01) -
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
by: Ganesh Pai, et al.
Published: (2017-08-01) -
Itolizumab in the Management of Psoriasis with Metabolic Syndrome
by: Shrichand G. Parasramani
Published: (2017-07-01) -
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
by: Anshu Kuriakose, et al.
Published: (2016-01-01) -
Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A Case Series of 20 Patients
by: Anchala Parthasaradhi
Published: (2016-11-01)